Option Care Health, Inc. OPCH R2K

Healthcare · Medical Care Facilities · United States

Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapy and services; home infusion services to treat heart failure; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. It also offers treatments to manage the progression of neurological disorders, such as Duchenne muscular dystrophy, multiple sclerosis, Alzheimer's disease, and other neurological disorder; infusion therapies for bleeding disorders, such as hemophilia and von Willebrand diseases; therapies for women with high-risk pregnancies; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications, as well as nursing services. The company markets its services through patient referrals, including physicians, hospital discharge planners, hospital personnel, health maintenance organizations, and preferred provider organizations. The company is headquartered in Bannockburn, Illinois.

Market & Price

Market Cap

$3.28B

Current Price

$20.87

High / Low (52W)

$36.59 / $19.52

Beta

0.68

Valuation

Stock P/E

16.30

Industry PE

23.65

Forward P/E

10.16

PEG Ratio

1.21

Book Value

$8.61

Price to Book

2.43

P/S

0.58

EV/EBITDA

10.88

Dividend Yield

Profitability & Returns

ROCE

12.85%

ROE

15.26%

ROA

6.19%

Profit Margin

3.64%

Op Margin

5.37%

EPS (Latest Qtr)

$0.29

EPS (TTM)

$1.28

Balance Sheet & Liquidity

Debt/Equity

0.94

Quick Ratio

1.01

Current Ratio

1.64

Debt

$1.27B

Total Assets

$3.46B

Current Assets

$1.26B

Working Capital

$435.62M

Ownership

Promoter Holding

1.20%

Chg in Prom Hold

FII / Inst Holding

110.03%

Chg in FII Hold

-0.02%

Financial Snapshot

Enterprise Value

$4.37B

Total Revenue (TTM)

$5.67B

EBITDA

$401.24M

Free Cash Flow

$168.69M

Operating Cash Flow

$253.55M

Shares Outstanding

157.03M

Gross Margin

19.18%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

12.72%

Profit 5Y

11.30%

Revenue (YoY)

1.30%

Earnings (YoY)

3.40%

PROS

Compounding revenue at 12.7% over 5 years.
Profit CAGR of 11.3% over 5 years.
Generates positive free cash flow.

CONS

Trading 43.0% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	OPCH Option Care Health, Inc. R2K	20.87	16.30	$3.28B	-	12.85%	15.26%	12.72%	11.30%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	217.81M	218.11M	198.69M	182.58M	460.64M	479.49M	493.93M	505.73M	476.49M	497.27M	615.88M	720.78M	705.44M	740.85M	781.61M	804.71M	759.24M	860.27M	891.94M	915.78M	980.82M	1.02B	1.02B	1.07B	1.09B	1.15B	1.23B	1.28B	1.33B	1.42B	1.44B	1.47B	1.35B
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.07B	1.15B	1.16B	1.18B	1.09B
Gross Profit	64.82M	65.23M	65.91M	63.30M	63.27M	61.72M	73.79M	64.87M	67.61M	66.56M	70.19M	101.70M	101.27M	108.25M	111.00M	98.19M	101.39M	137.77M	175.64M	158.03M	166.32M	174.15M	183.76M	165.47M	198.97M	202.97M	200.94M	216.90M	218.00M	229.00M	250.83M	254.27M	238.50M	249.37M	256.75M	263.05M	269.04M	272.90M	282.90M	262.01M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	183.86M	186.33M	188.40M	191.40M	189.47M
Operating Income	-254.00M	-19.28M	-	-1.27M	-	-	-	-	-	-	-	3.06M	8.90M	12.76M	13.55M	5.44M	-8.01M	-11.72M	13.97M	8.65M	23.21M	34.56M	44.34M	29.09M	48.09M	52.88M	52.24M	59.08M	60.72M	66.62M	82.37M	81.05M	69.03M	80.67M	85.09M	79.19M	82.71M	84.51M	91.50M	72.55M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	93.16M	100.26M	100.16M	114.57M	89.96M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	13.23M	14.45M	14.15M	12.73M	13.30M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	63.56M	68.86M	68.97M	81.52M	61.00M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	16.81M	18.34M	17.15M	23.01M	15.66M
Net Income	-244.81M	-16.78M	-18.44M	-9.83M	-8.75M	-11.33M	-12.86M	-19.72M	-29.52M	-12.99M	-1.96M	-6.85M	-4.31M	1.79M	3.25M	-3.71M	-13.60M	-42.79M	-15.81M	-19.91M	-7.67M	1.66M	17.84M	-2.86M	31.82M	35.48M	30.27M	33.93M	38.82M	39.21M	114.40M	56.30M	44.79M	53.04M	53.86M	46.74M	50.52M	51.82M	58.50M	45.34M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-0.15	-0.14	-	-	-0.03	-0.10	-0.26	-0.09	-0.11	-0.04	0.01	0.10	-0.02	0.18	0.20	0.17	0.19	0.21	0.21	0.63	0.31	0.26	0.30	0.31	0.28	0.31	0.32	0.37	0.29

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	-	-	-	-	935.59M	1.83B	1.94B	2.31B	3.03B	3.44B	3.94B	4.30B	5.00B	5.65B
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.08B	3.32B	3.99B	4.56B
Gross Profit	137.01M	142.17M	157.82M	160.54M	215.41M	195.90M	206.65M	250.75M	259.95M	262.08M	446.00M	422.21M	513.00M	682.26M	779.61M	866.92M	981.22M	1.01B	1.09B
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	626.69M	666.63M	691.16M	749.99M
Operating Income	8.85M	-83.52M	15.47M	7.54M	25.55M	6.68M	-26.25M	-97.81M	-287.65M	-10.99M	27.28M	38.27M	-319.00K	110.75M	190.84M	240.23M	314.60M	321.83M	337.91M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	325.01M	472.19M	396.13M	408.15M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	53.81M	51.25M	49.03M	54.56M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	205.77M	358.74M	283.60M	282.90M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	55.21M	91.65M	71.78M	75.31M
Net Income	3.32M	-74.03M	54.10M	-69.14M	7.87M	64.71M	-69.65M	-147.47M	-300.13M	-42.77M	3.88M	-6.12M	-75.92M	-8.08M	139.90M	150.56M	267.09M	211.82M	207.59M
Diluted EPS	0.09	-1.93	1.36	-1.37	0.14	1.15	-	-	-	-	-	-	-0.49	-0.04	0.77	0.83	1.48	1.23	1.27

Compounded Sales Growth

5 Years:	12.72%
1 Year:	1.30%

Compounded Profit Growth

5 Years:	11.30%
1 Year:	3.40%

Stock Price Performance

1 Year:	-36.14%
6 Months:	-33.15%
3 Months:	-35.71%
1 Month:	-22.33%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2006	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Jun 2018	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	246.96M	287.22M	663.99M	677.10M	642.38M	936.86M	824.71M	530.64M	604.99M	603.09M	-	1.43B	2.59B	2.65B	-	3.11B	3.22B	3.42B	3.46B
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	994.34M	1.09B	1.32B	1.26B
Cash & Equivalents	0	0	0	0	0	0	62.10M	1.00M	740.00K	15.58M	9.57M	39.46M	-	36.39M	67.06M	99.27M	-	294.19M	343.85M	412.56M	232.62M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	224.28M	274.00M	388.13M	471.15M
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	377.54M	377.66M	409.73M	473.57M
Total Liabilities	-	-	151.42M	131.43M	463.88M	461.82M	348.97M	582.27M	607.91M	548.60M	566.60M	605.76M	-	825.39M	1.68B	1.63B	-	1.73B	1.80B	2.02B	2.13B
Current Liabilities	-	-	147.80M	128.20M	226.79M	220.77M	108.27M	176.32M	163.25M	152.76M	130.15M	105.13M	-	240.00M	330.00M	434.02M	-	565.35M	618.31M	780.15M	829.35M
Long Term Debt	-	-	-	-	225.12M	227.30M	225.43M	375.32M	-	-	-	-	-	535.23M	1.28B	1.12B	-	1.06B	1.06B	1.10B	1.15B
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.16B	1.17B	1.22B	1.27B
Total Equity	161.83M	166.20M	95.54M	155.79M	200.10M	215.28M	293.41M	354.58M	216.59M	-81.52M	600.77M	606.11M	602.83M	602.83M	906.83M	1.02B	-	1.39B	1.42B	1.40B	1.33B
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	182.34M	182.91M	183.85M	184.52M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	24.19M	-8.75M	22.75M	-21.42M	26.97M	26.88M	-54.58M	-31.42M	-64.23M	-42.54M	37.87M	24.43M	39.47M	127.39M	-	267.55M	371.30M	323.39M	258.45M
Investing Cash Flow	-5.53M	-7.46M	-5.74M	-108.28M	-9.91M	93.88M	-302.34M	44.26M	12.51M	-73.21M	-24.47M	-37.00M	-727.83M	-26.33M	-	-108.05M	-56.51M	-36.47M	-161.08M
Financing Cash Flow	-18.66M	16.21M	-17.01M	129.70M	-17.06M	-58.66M	295.82M	-13.10M	66.56M	109.74M	-5.15M	-4.15M	719.02M	-68.85M	-	15.27M	-265.13M	-218.21M	-277.31M
Capital Expenditure	-	-	-	-	-	-	-	-	-	-	-24.96M	-26.28M	-28.29M	-26.88M	-	-35.36M	-41.87M	-35.61M	-41.31M
Free Cash Flow	-	-	-	-	-	-	-	-	-	-	12.91M	-1.85M	11.18M	100.52M	-	232.19M	329.43M	287.79M	217.14M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	174.76M	49.66M	68.72M	-179.94M
Share Buybacks	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	250.26M	252.73M	309.95M

Ratios (Annual)

Figures in %.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	28.0%	24.4%	21.8%	22.2%	22.5%	22.7%	22.0%	22.8%	20.3%	19.3%
Operating Margin %	-	-	-	-	-	-	-	-	-	-1.2%	1.5%	2.0%	-0.0%	3.7%	5.5%	6.1%	7.3%	6.4%	6.0%
Net Margin %	-	-	-	-	-	-	-	-	-	-4.6%	0.2%	-0.3%	-3.3%	-0.3%	4.1%	3.8%	6.2%	4.2%	3.7%
ROE %	2.0%	-77.5%	34.7%	-34.6%	3.7%	22.1%	-19.6%	-68.1%	368.2%	-7.1%	0.6%	-1.0%	-8.4%	-0.8%	-	10.9%	18.8%	15.1%	15.7%
ROCE %	-	-84.2%	9.7%	1.7%	5.6%	1.2%	-3.5%	-14.8%	-76.1%	-2.3%	5.5%	3.2%	-0.0%	5.0%	-	9.4%	12.1%	12.2%	12.9%

Shareholding Pattern

Insiders

1.20%

Institutions

110.03%

Public Float

111.37%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	12.67%	19.89M	$415.06M
2	Wellington Management Group, LLP	7.58%	11.90M	$248.30M
3	Durable Capital Partners Lp	5.73%	8.99M	$187.65M
4	Vanguard Portfolio Management LLC	5.13%	8.06M	$168.27M
5	Fuller & Thaler Asset Management Inc.	4.54%	7.13M	$148.70M
6	Vanguard Capital Management LLC	4.47%	7.02M	$146.43M
7	FMR, LLC	4.09%	6.43M	$134.11M
8	State Street Corporation	3.74%	5.87M	$122.61M
9	Geode Capital Management, LLC	2.71%	4.25M	$88.66M
10	Arrowstreet Capital, Limited Partnership	2.70%	4.24M	$88.41M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for OPCH

No recent headlines available.

OPCH · Healthcare